Shares of hVIVO plc (LON:HVO – Get Free Report) were down 6.8% during mid-day trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.26).
hVIVO Stock Performance
The firm has a fifty day moving average of GBX 23.58 and a 200 day moving average of GBX 26.77. The stock has a market cap of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
- Five stocks we like better than hVIVO
- Using the MarketBeat Dividend Tax Calculator
- 3 Legacy Tech Companies Reemerging as AI Leaders
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Trading Halts Explained
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.